Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. DH
DH logo

DH Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
0.901
Open
0.900
VWAP
0.87
Vol
354.22K
Mkt Cap
123.62M
Low
0.856
Amount
309.04K
EV/EBITDA(TTM)
2.62
Total Shares
143.75M
EV
156.51M
EV/OCF(TTM)
3.98
P/S(TTM)
0.39
Definitive Healthcare Corp. is engaged in transforming data, analytics, and expertise into healthcare commercial intelligence. The Company’s solutions are designed to provide information on healthcare providers and their activities to help its customers optimize everything from product development to go-to-market planning and sales and marketing execution. Its software-as-a-service (SaaS) platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers and improving win rates with detailed contextual information. It transforms data into intelligence through artificial intelligence (AI) and machine learning (ML) algorithms that ingest, cleanse, link, and analyze the data to create new intelligence and analytics. Its business is conducted through AIDH TopCo, LLC (Definitive OpCo).
Show More

Events Timeline

(ET)
2026-05-07
17:20:00
Sees Q2 Revenue of $55M-$56M
select
2026-05-07
17:20:00
Company Confirms FY26 Revenue Outlook of $220M to $226M
select
2026-05-07
17:20:00
Definitive Healthcare Q1 Revenue $55.93M, Exceeds Expectations
select

News

seekingalpha
9.5
05-08seekingalpha
Definitive Healthcare Corp. Q1 2026 Earnings Call Insights
  • Revenue and Profit Performance: Definitive Healthcare reported total revenue of $55.9 million in Q1, a 6% year-over-year decline; however, adjusted EBITDA reached $15.3 million, reflecting a 27% margin, exceeding guidance by $2.3 million, indicating effective cost management.
  • Cash Flow and Business Growth: The company generated approximately $50 million of unlevered free cash flow over the past 12 months, and despite a decline in Life Sciences, the Diversified and Provider segments, which account for over 60% of total revenue, demonstrated resilience and modest growth.
  • Integration and Innovation Progress: In Q1, nearly 50 new customer integrations were completed, with integration time reduced by nearly 50% year-over-year, while the company expects to launch its first AI-enabled solutions later this quarter, showcasing its commitment to technological innovation.
  • Future Outlook and Guidance: The company anticipates total revenue of $55 million to $56 million for Q2, with adjusted EBITDA projected between $13.5 million and $14.5 million, and full-year revenue guidance set at $220 million to $226 million, reflecting management's confidence in future growth.
seekingalpha
9.5
05-07seekingalpha
Definitive Healthcare Q1 Earnings Report Analysis
  • Earnings Performance: Definitive Healthcare reported a Q1 GAAP EPS of -$1.32, missing expectations by $1.25, indicating challenges in profitability that may affect investor confidence.
  • Revenue Growth: The company achieved Q1 revenue of $55.9M, exceeding expectations by $0.92M, suggesting an improvement in market demand, although overall profitability remains a concern.
  • Future Outlook: For Q2, revenue is expected to range between $55.0M and $56.0M, with adjusted operating income projected at $10.5M to $11.5M, reflecting a cautiously optimistic view on future growth.
  • Annual Forecast: For the full year 2026, revenue is anticipated to be between $220.0M and $226.0M, with adjusted net income expected to be $23.0M to $27.0M, demonstrating the company's ongoing commitment to long-term growth strategies.
Benzinga
2.0
03-05Benzinga
Investment Opportunities in Oversold Healthcare Stocks
  • Oversold Stocks Overview: In the healthcare sector, Gossamer Bio Inc, Brainsway Ltd, and Definitive Healthcare Corp have relative strength indices (RSI) near or below 30, indicating these stocks are significantly undervalued and may present buying opportunities for investors.
  • RSI Indicator Interpretation: The relative strength index (RSI) serves as a momentum indicator that compares a stock's strength on up days versus down days, helping traders better assess short-term stock performance, particularly in oversold conditions.
  • Market Opportunity Analysis: According to Benzinga Pro, assets are typically considered oversold when the RSI is below 30, providing investors with opportunities to identify potential rebound stocks within the healthcare sector that could yield substantial returns.
  • Investment Strategy Recommendations: Investors should focus on the fundamentals and market dynamics of these oversold stocks to make informed investment decisions at the right time, thereby capitalizing on profit opportunities arising from market fluctuations.
seekingalpha
9.5
02-26seekingalpha
Definitive Healthcare Q4 Earnings Report Analysis
  • Earnings Performance: Definitive Healthcare reported a Q4 GAAP EPS of -$0.09, missing the expected -$0.06, indicating ongoing profitability pressures that could undermine investor confidence.
  • Revenue Details: The company posted revenues of $61.5 million, a 1.3% year-over-year decline, although it slightly exceeded expectations of $61.31 million; however, the ongoing revenue decline poses challenges for future growth prospects.
  • Market Reaction: Given the earnings miss, market reactions to the company's stock may lean negative, prompting investors to closely monitor subsequent strategic adjustments and market adaptability.
  • Future Outlook: Despite slightly surpassing revenue expectations, the persistent losses and declining revenues may compel management to reassess its business strategy to restore market confidence and drive long-term growth.
NASDAQ.COM
8.5
2025-12-05NASDAQ.COM
Advent International Invests $2.35 Billion to Make NIQ Its Leading Investment
  • Advent International's Investment: Boston-based Advent International has acquired a new stake in NIQ Global Intelligence plc, purchasing 149,380,246 shares valued at approximately $2.35 billion, making it the fund's largest holding.

  • Financial Overview of NIQ: As of September 30, 2025, NIQ reported trailing twelve months revenue of $4.01 billion and a net loss of $434.36 million, with shares priced at $14.18, which is 30.46% below its 52-week high.

  • NIQ's Market Position: NIQ operates globally with over 38,000 employees, providing an AI-powered consumer intelligence platform that analyzes shopping data to deliver insights for brands and retailers, playing a crucial role in consumer behavior analysis.

  • Investment Implications: Advent's significant investment suggests confidence in NIQ's long-term value despite current market pressures, as the company seeks to convert its data capabilities into consistent free cash flow while managing its debt load.

Globenewswire
7.5
2025-12-03Globenewswire
De Havilland Partners with Avincis to Enhance CL Series Aircraft Services
  • Collaboration Agreement: De Havilland and Avincis have established a partnership where Avincis transfers its ADS-B and FMS supplemental type certificates for CL aircraft to De Havilland, enhancing the spare parts catalog and improving access to critical system solutions for global CL aircraft operators.
  • Market Responsiveness: This collaboration enables De Havilland to better serve Avincis, the largest operator of CL-415 aircraft globally, which is expected to enhance customer satisfaction and strengthen market competitiveness.
  • Design and Maintenance Capabilities: Avincis brings over 20 years of operational experience with CL-415 aircraft, providing robust design and maintenance capabilities that will deliver high-quality solutions to global CL aircraft operators, further solidifying its market position.
  • Commitment to Ongoing Investment: This partnership is part of De Havilland's ongoing investment and commitment to CL aircraft customers, demonstrating the company's dedication to enhancing its service capabilities in the global aviation market through collaboration with Avincis.
Wall Street analysts forecast DH stock price to rise
9 Analyst Rating
Wall Street analysts forecast DH stock price to rise
3 Buy
5 Hold
1 Sell
Hold
Current: 0.000
sliders
Low
2.75
Averages
3.71
High
5.00
Current: 0.000
sliders
Low
2.75
Averages
3.71
High
5.00
Baird
Neutral
downgrade
AI Analysis
2026-05-08
Reason
Baird
Price Target
AI Analysis
2026-05-08
downgrade
Neutral
Reason
Baird lowered the firm's price target on Definitive Healthcare to $1.10 from $1.30 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results.
Barclays
Underweight
downgrade
$1
2026-03-30
Reason
Barclays
Price Target
$1
2026-03-30
downgrade
Underweight
Reason
Barclays lowered the firm's price target on Definitive Healthcare to $1 from $2.75 and keeps an Underweight rating on the shares. The firm updated models in healthcare technology to reflect recent results and management commentary.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for DH
Unlock Now

Valuation Metrics

The current forward P/E ratio for Definitive Healthcare Corp (DH.O) is 5.98, compared to its 5-year average forward P/E of 47.24. For a more detailed relative valuation and DCF analysis to assess Definitive Healthcare Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
47.24
Current PE
5.98
Overvalued PE
95.47
Undervalued PE
-0.99

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
20.97
Current EV/EBITDA
3.02
Overvalued EV/EBITDA
38.24
Undervalued EV/EBITDA
3.69

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
4.83
Current PS
0.43
Overvalued PS
9.12
Undervalued PS
0.55

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

highest option premium stocks
Intellectia · 46 candidates
Is Optionable: TrueOption Iv Rank: >= 80
Ticker
Name
Market Cap$
top bottom
OSG logo
OSG
Octave Specialty Group Inc
207.68M
CNNE logo
CNNE
Cannae Holdings Inc
563.31M
CBAN logo
CBAN
Colony Bankcorp Inc
429.04M
GENC logo
GENC
Gencor Industries Inc
220.31M
PLOW logo
PLOW
Douglas Dynamics Inc
970.25M
MBLY logo
MBLY
Mobileye Global Inc
6.27B
what penny stocks to buy pre market 4/1/26
Intellectia · 14 candidates
Market Cap: 100.00M - 2.00BRegion: USVolume: >= 200,000Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEPre Market Price Change: $3.00 - $20.00
Ticker
Name
Market Cap$
top bottom
TLRY logo
TLRY
Tilray Brands Inc
753.80M
OMER logo
OMER
Omeros Corp
748.71M
VOR logo
VOR
Vor Biopharma Inc
871.44M
VALN logo
VALN
Valneva SE
542.98M
SLNO logo
SLNO
Soleno Therapeutics Inc
1.73B
SGMO logo
SGMO
Sangamo Therapeutics Inc
102.28M

Whales Holding DH

A
Advent International, L.P.
Holding
DH
-10.04%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Definitive Healthcare Corp (DH) stock price today?

The current price of DH is 0.86 USD — it has decreased -2.93

What is Definitive Healthcare Corp (DH)'s business?

Definitive Healthcare Corp. is engaged in transforming data, analytics, and expertise into healthcare commercial intelligence. The Company’s solutions are designed to provide information on healthcare providers and their activities to help its customers optimize everything from product development to go-to-market planning and sales and marketing execution. Its software-as-a-service (SaaS) platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers and improving win rates with detailed contextual information. It transforms data into intelligence through artificial intelligence (AI) and machine learning (ML) algorithms that ingest, cleanse, link, and analyze the data to create new intelligence and analytics. Its business is conducted through AIDH TopCo, LLC (Definitive OpCo).

What is the price predicton of DH Stock?

Wall Street analysts forecast DH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DH is3.71 USD with a low forecast of 2.75 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Definitive Healthcare Corp (DH)'s revenue for the last quarter?

Definitive Healthcare Corp revenue for the last quarter amounts to 55.93M USD, decreased -5.51

What is Definitive Healthcare Corp (DH)'s earnings per share (EPS) for the last quarter?

Definitive Healthcare Corp. EPS for the last quarter amounts to -1.32 USD, increased 38.95

How many employees does Definitive Healthcare Corp (DH). have?

Definitive Healthcare Corp (DH) has 686 emplpoyees as of May 15 2026.

What is Definitive Healthcare Corp (DH) market cap?

Today DH has the market capitalization of 123.62M USD.